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Background: Previous studies have suggested that DNA methylation contributes to coronary artery disease (CAD)
risk variability. DNA hypermethylation at the ATP-binding cassette transporter A1 (ABCA1) gene, an important
modulator of high-density lipoprotein cholesterol and reverse cholesterol transport, has been previously associated
with plasma lipid levels, aging and CAD, but the association with CAD has yet to be replicated.
Results: ABCA1 DNA methylation levels were measured in leucocytes of 88 men using bis-pyrosequencing. We first
showed that DNA methylation at the ABCA1 gene promoter locus is associated with aging and CAD occurrence in
men (P < 0.05). The latter association is stronger among older men with CAD (≥61 years old; n = 19), who showed
at least 4.7% higher ABCA1 DNA methylation levels as compared to younger men with CAD (<61 years old; n = 19)
or men without CAD (n = 50; P < 0.001). Higher ABCA1 DNA methylation levels in older men were also associated
with higher total cholesterol (r = 0.34, P = 0.03), low-density lipoprotein cholesterol (r = 0.32, P = 0.04) and triglyceride
levels (r = 0.26, P = 0.09). Furthermore, we showed that acetylsalicylic acid therapy is associated with 3.6% lower
ABCA1 DNA methylation levels (P = 0.006), independent of aging and CAD status of patients.
Conclusions: This study provides new evidence that the ABCA1 epigenetic profile is associated with CAD and
aging, and highlights that epigenetic modifications might be a significant molecular mechanism involved in the
pathophysiological processes associated with CAD. Acetylsalicylic acid treatment for CAD prevention might involve
epigenetic mechanisms.
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The ATP-binding cassette transporter A1 (ABCA1) cata-
lyzes the transfer of lipids from various tissues and cells to
apolipoprotein A1 containing lipoproteins [1]. This reaction
is the rate-limiting step in the biogenesis of high-density
lipoprotein particles and reverse cholesterol transport [1].
Mutations within the ABCA1 gene in humans are respon-
sible for Tangier disease (OMIM: 2054000) and familial
hypoalphalipoproteinemia (OMIM: 604091) [2-4]. These* Correspondence: luigi.bouchard@usherbrooke.ca
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duced plasma high-density lipoprotein cholesterol (HDL-C)
levels, the accumulation of cholesterol esters in peripheral
tissues and an increased risk of coronary artery disease
(CAD) [2-6].
Previous candidate gene and genome-wide studies have
suggested that DNA methylation contributes to CAD risk
variability [7-13]. Indeed, we have recently shown that a
higher DNA methylation level at the ABCA1 gene pro-
moter locus was associated with lower HDL-C levels and
a previous history of CAD in familial hypercholeste-
rolemia (FH) [7]. Moreover, our group and others have
shown that higher ABCA1 DNA methylation levels were
associated with a lower ABCA1 gene expression [14,15].
All these previous results suggest that perturbations of thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mechanism involved in CAD. However, these results have
not yet been replicated.
DNA methylation is a non-traditional heritable factor
occurring at cytosines located upstream of a guanine
(CpG dinucleotides). It is involved in gene expression
regulation [16]. This epigenetic modification is mitotically
stable, and several environmental factors modulate its
levels across the genome [16]. Interestingly, we recently
observed that ABCA1 DNA methylation level variability
in newborns is associated with maternal glycemic and
HDL-C status, suggesting that the in utero environment
might modulate the ABCA1 epigenetic profile [14]. More-
over, previous epigenetic studies performed by researchers
from The Netherlands showed that aging and prenatal
famine exposure are associated with DNA hypermethyla-
tion at the ABCA1 gene promoter locus [17,18]. Overall,
these results suggest that both the in utero and postnatal
environments might modulate the ABCA1 epigenetic pro-
file and trigger a long-term susceptibility to cardiovascular
diseases (CVDs) [14,17,18].
Environmental cardiovascular risk factors, such as
smoking, a high-fat diet and physical activity, have been
previously associated with DNA methylation variability in
humans [19-22]. More interestingly, statins and acetyl-
salicylic acid (ASA), two drugs frequently prescribed to
patients with a high cardiovascular risk profile, have been
shown to be associated with the induction or attenuation
of epigenetic marks in vitro [23,24]. However, no study
has yet determined whether environmental cardiovascular
risk factors or medication might be associated with the
ABCA1 DNA methylation profile in humans.
The aims of this study were thus to replicate the asso-
ciation between ABCA1 DNA methylation and CAD in
a non-FH population, as well as assess whether aging
and environmental factors, especially tobacco smoking
and medication, might be associated with ABCA1 DNA
methylation in a sample of 88 French-Canadian men.
Results
Table 1 shows the characteristics of subjects according to
their CAD status and median age (61 years old). We first
assessed whether mean DNA methylation levels at 8 CpG
dinucleotides located at the ABCA1 gene promoter locus
might be associated with CAD occurrence and aging in
men (Figure 1). We observed that men with a previous
history of CAD (n = 38) showed higher mean ABCA1
DNA methylation levels than men without CAD (n = 50)
(38.7 ± 1.2 versus 36.0 ± 1.0, P = 0.04; after consideration of
age and current treatments) (Figure 1A). Moreover, older
men (age ≥61 years old) had higher mean ABCA1 DNA
methylation levels than younger men (age <61 years old)
(38.0 ± 1.2 versus 35.2 ± 1.0, P = 0.02; after consideration of
CAD occurrence and current treatments) (Figure 1B).Interestingly, we also observed a significant interaction
between CAD status and age on mean ABCA1 DNA
methylation levels (P = 0.01; Figure 2). Older men with
CAD (age ≥61 years old; n = 19) showed significantly
higher DNA methylation levels at the ABCA1 gene
promoter locus compared to younger men without CAD
(age <61 years old), older men without CAD (age ≥61 years
old) and younger men with CAD (age <61 years old)
(Table 1 and Figure 2), independently of current treat-
ment. No significant mean ABCA1 DNA methylation level
difference was observed between younger men with or
without CAD (P = 0.67). In older men (age ≥61 years old),
we also observed that a higher ABCA1 DNA methylation
level was positively correlated with total cholesterol
(r = 0.34; P = 0.03), low-density lipoprotein cholesterol
(r = 0.32; P = 0.04), as well with fasting triglyceride levels
(trend; r = 0.26; P = 0.09) after consideration of age, CAD
status and medication. In younger men (age <61 years
old), no significant association was observed between
mean ABCA1 DNA methylation levels and plasma lipid
profile (data not shown).
Next, we further assessed whether smoking and medi-
cation were associated with the ABCA1 epigenetic pro-
file in men. No significant association was observed
between ABCA1 DNA methylation levels and tobacco
smoking status (data not showed). However, we ob-
served that subjects under ASA treatment (n = 42) had
significantly lower mean DNA methylation levels at the
ABCA1 gene promoter locus compared to subjects not
taking ASA (n = 46), even when the statistical model was
adjusted for age and CAD (Figure 3). ABCA1 DNA
methylation levels measured at all eight CpGs were sig-
nificantly associated with ASA treatment (all P < 0.008).
No significant association was observed between ABCA1
DNA methylation levels and the use of other medica-
tions (data not shown).
Discussion
Previous work from our group and others has shown
that ABCA1 DNA methylation is associated with aging,
dyslipidemia and CAD [7,18]. In the current study, we
provide the first confirmatory evidence that a higher
DNA methylation level at the ABCA1 gene is indepen-
dently associated with CAD, an association that might
be specific to older men. We also provide additional vali-
dation of the independent associations with age and a
proatherogenic lipid profile. As previously described, the
relationship between dyslipidemia, CAD and higher
DNA methylation levels at the ABCA1 gene promoter
locus (associated with a lower ABCA1 gene expression)
suggests that the ABCA1-driven reverse cholesterol
transport is compromised when ABCA1 DNA methyla-
tion increases [7,14,15]. This could lead to an increased
susceptibility to CAD as seen in Tangier disease or
Table 1 Characteristics of men according to their coronary artery disease status
Characteristics Younger men withoutCAD (n = 25)
Older men without
CAD (n = 25)
Younger men with
CAD (n = 19)
Older men with
CAD (n = 19) P-value
Adjusted
P-valuea
Age (years) 53.6 ± 1.4 72.6 ± 1.5 54.3 ± 1.9 73.4 ± 1.9 <0.001 -
BMI (kg/m2) 28.1 ± 1.1 27.0 ± 0.7 29.0 ± 1.2 26.3 ± 0.5 0.21 0.33
Waist circumference (cm) 100.4 ± 3.2 99.9 ± 1.7 102.2 ± 3.3 100.6 ± 1.7 0.94 0.81
Glucose (mmol/L) 5.12 ± 0.23 5.73 ± 0.20 6.00 ± 0.27 5.50 ± 0.20 0.06 0.06
Total cholesterol (mmol/L) 4.61 ± 0.20 3.78 ± 0.21 4.33 ± 0.30 3.91 ± 0.19 0.03 0.48
LDL-C (mmol/L) 2.58 ± 0.16 2.02 ± 0.17 2.67 ± 0.27 2.14 ± 0.16 0.04 0.63
HDL-C (mmol/L) 1.22 ± 0.08 1.16 ± 0.06 1.03 ± 0.05 1.12 ± 0.06 0.21 0.20
Fasting triglyceridemia (mmol/L)b 1.58 ± 0.37 1.22 ± 0.14 1.48 ± 0.12 1.33 ± 0.11 0.27 0.79
Smoking (ever/never) 15/10 14/11 14/5 9/9 0.50 -
Medication (%)
ARB 4 (16) 5 (20) 5 (26.3) 4 (21.1) 0.89 -
ASA 6 (24) 9 (36) 11 (57.9) 16 (84.2) <0.001 -
β-Blocker 8 (32) 7 (28) 9 (47.4) 11 (57.9) 0.16 -
Diuretic 8 (32) 10 (40) 3 (15.8) 5 (26.3) 0.36 -
Calcium channel blocker 2 (8) 6 (24) 9 (47.4) 7 (36.8) 0.02 -
Lipid-lowering drugs 8 (32) 17 (68) 12 (63.2) 18 (94.7) 0.003 -
ACE inhibitors 11 (44) 8 (32) 8 (42.1) 6 (31.6) 0.75 -
Nitroglycerine 1 (4) 4 (16) 5 (26.3) 9 (47.4) 0.005 -
Mean ABCA1 DNA methylation (%) 36.1 ± 1.5 35.9 ± 1.5 33.9 ± 1.3 40.7 ± 2.0c,d,e 0.04 <0.001
Results are shown as mean ± SEM unless otherwise stated. Statistically significant results are shown in bold. aP-values were obtained following an analysis of covariance
including age and ASA as covariables. bGeometric mean and P-value obtained after log10-transformation of the variable. cP ≤ 0.05, compared to younger men without CAD
following Bonferroni’s post-hoc comparison test; dP < 0.05 compared to older men without CAD following Bonferroni’s post-hoc comparison test; eP < 0.05 compared to
younger men with CAD following Bonferroni’s post-hoc comparison test. ABCA1, ATP-binding cassette transporter A1; ACE, angiotensin-converting enzyme; ARB, aldosterone
receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; CAD, coronary artery disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol.
Figure 1 ABCA1 DNA methylation levels in leucocytes according to coronary artery disease occurrence and aging. Men with a previous
history of coronary artery disease (CAD) (A) and older men (B) showed higher mean ATP-binding cassette transporter A1 (ABCA1) DNA methylation
levels compared to men without history of CAD and younger men, respectively. aP-values were obtained after consideration of patients’ current
treatments and age. bP-values were obtained after consideration of patients’ current treatments, CAD status and age.
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Figure 2 Interaction between coronary artery disease and
aging on ABCA1 DNA methylation levels in leucocytes. Older
men (>61 years old) with coronary artery disease (CAD) had the
highest mean ATP-binding cassette transporter A1 (ABCA1) DNA
methylation levels. CAD occurrence and aging interact to increase
ABCA1 DNA methylation levels in leucocytes (P = 0.01). P-values were
obtained after consideration of acetylsalicylic acid treatment.
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higher ABCA1 DNA methylation levels observed in older
men with CAD could also be related to an increased se-
verity of CAD or a longer disease history in these patients,
but this relation will have to be confirmed. Nonetheless,
the association between ABCA1 DNA methylation and
CAD that we first observed in FH subjects has now been
replicated in men with common hypercholesterolemia.Figure 3 Association between ABCA1 DNA methylation levels
and acetylsalicylic acid therapy. Subjects on acetylsalicylic acid
(ASA) therapy had lower mean ATP-binding cassette transporter A1
(ABCA1) DNA methylation levels (Δ = −3.6%) compared to subjects
not on ASA therapy, independent of age and CAD. In subjects
without CAD, we observed the same significant association between
ASA and a lower mean ABCA1 DNA methylation level (Δ = −4.7%;
P = 0.01). Although not significant, we observed that in subjects with
CAD, those under an ASA treatment exhibited a similar decrease in
mean ABCA1 DNA methylation levels (Δ = −3.9%; P = 0.14). aP-values
were obtained after consideration of age. bP-value was obtained
after consideration of age and CAD status.Recently, results reported by Tobi and colleagues and
our group also suggested that adverse fetal environmen-
tal conditions might have persistent epigenetic conse-
quences on the ABCA1 epigenetic profile and predispose
newborns to develop obesity, diabetes and CVD [14,17].
However, it was additionally suggested that the postnatal
environment might also modulate the DNA methylome
[19-22]. The increased ABCA1 DNA methylation that
we observed with aging in men with CAD could thus
illustrate the effects of an accumulation of exposures to
pro-CAD environmental factors (such as a high-fat diet,
physical inactivity or tobacco smoking) that induces
ABCA1 DNA methylation variability over time and pre-
disposes to CVD. In the current study, we did not
observe a significant association between the tobacco
smoking status of men and ABCA1 DNA methylation
although smoking has already been associated with DNA
methylation changes at other loci [19]. Unfortunately, it
has not been possible to assess the association with other
postnatal environmental exposures (diet or physical acti-
vity). Nevertheless, these results provide evidence in sup-
port of longitudinal and interventional studies.
Interestingly, we observed that subjects on ASA treat-
ment had lower ABCA1 DNA methylation levels compared
to those not under this non-steroidal anti-inflammatory
drug (NSAID) treatment. It has been previously suggested
that ASA treatment is associated with a decrease of the
concentration of atherogenic lipids, an increase of HDL-C
levels, as well as the variability of gene expression levels of
ABCA1 and other key genes involved in reverse cholesterol
transport in humans [25-28]. Previous epigenetic studies
have shown that ASA and other NSAIDs might induce
DNA methylation changes in humans [29-31]. Indeed, it
has been suggested that ASA use might reduce the me-
thylation rate associated with aging, especially at cancer-
related genes [32]. More recently, Chang and colleagues
suggested that ASA lowers the CAD risk by an epigenetic
mechanism that protects against atherogenic electronega-
tive low-density lipoprotein particles [23]. However, the
mechanism by which ASA induces DNA methylation
variability is still unknown, but likely involves its anti-
inflammatory properties [30]. Indeed, inflammation has
been known to promote de novo methylation, and ASA
might therefore decrease DNA methylation levels at in-
flammatory-sensitive loci through its anti-inflammatory
properties [30]. Based on these preliminary results and the
current literature, it is tempting to speculate that ASA
treatment lowers the CAD risk by reducing inflammation
and ABCA1 gene DNA methylation levels, leading in turn
to the stimulation of the reverse cholesterol transport. Al-
though this hypothesis will have to be confirmed in larger
cohorts before strong conclusions can be drawn, our study
brings new and promising research hypotheses to the
fields of lipid research and pharmacoepigenetics.
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and reproducible technology for DNA methylation quanti-
fication (that is, pyrosequencing of bisulfite-treated DNA).
In addition, our sample size, although small for association
studies, was fairly large compared with that of other
epigenetic studies. Importantly, it allowed us to take into
account possible confounding factors [11-13]. A limitation
of this study relates to the impossibility to infer the causal
relationship observed between ABCA1 DNA methylation
and CAD. Indeed, a patient’s methylome can either be
modulated by CAD occurrence or be a molecular me-
chanism leading to CAD. Also, our study focused only on
men in order to control for the possible confounding
effects of sex hormones. It follows that our conclusions
might not apply to women considering that the CAD risk
profile might be associated with different epigenetically
modulated loci in men and women. Finally, a candidate
gene approach might seem less attractive compared to re-
cent genome-wide methylation analyses [10,33]. However,
we would like to point out that the ABCA1 gene promoter
locus analyzed in the current study is not assessed on
the Infinium HumanMethylation27 and HumanMethyla-
tion450 BeadChips, the most widely used genome-wide
methylation technologies. This clearly illustrates that can-
didate gene approaches are still essential, even in the
current microarray era.
Conclusions
This study confirms that higher DNA methylation levels
at the ABCA1 gene promoter locus are associated with
aging and CAD in men. It supports the recently uncov-
ered epigenetics-related cardioprotective effects of ASA
treatment. It also provides the results of one of the few -
though greatly needed - replication studies in epigenetic
epidemiology. Overall, these findings could help our un-
derstanding of the molecular mechanisms involved in the
pathophysiological processes leading to CAD in men and,
in time, the development of new therapeutic strategies.
Methods
Sample and clinical data
This study included 88 men with (n = 38) and without
CAD (n = 50) recruited from patients who underwent
heart surgery at the Institut universitaire de cardiologie
et de pneumologie de Québec (IUCPQ). All patients
with and without CAD were caucasians (of French
Canadian origin). Men with CAD were selected from pa-
tients undergoing coronary artery bypass grafting with a
pre-operative angiogram showing the presence of at least
one lesion of 50%. The average number of grafts per
patient was 2.95 ± 1.55 (range 1 to 6). Only two patients
had been diagnosed with acute coronary syndrome. Pa-
tients with a normal angiogram were selected as controls
among individuals undergoing isolated valve surgery. Allsubjects were normoglycemic, and it was unlikely that
they were FH based on their clinical history and the low
prevalence of this inherited condition in the Quebec City
area where they were recruited (prevalence of 1 FH sub-
ject on 208 inhabitants [34]. The subjects’ current treat-
ments/medications (aldosterone receptor blocker, ASA,
β-blocker, diuretic, calcium channel blocker, lipid-lower-
ing drugs, angiotensin-converting-enzyme inhibitor and
nitroglycerine), as well as their smoking status (current,
former or never) were recorded. Patients signed an in-
formed consent to include biological material and corre-
sponding clinical data in our local biobank of the Centre
de Recherche de l’IUCPQ (CRIUCPQ). This project re-
ceived the approval of the IUCPQ ethics committee.
Fasting blood samples were obtained preoperatively.
Plasma cholesterol, triglyceride and glucose concentrations
were enzymatically measured using standard procedures.
Nucleic acid extraction and DNA methylation level
measurement
DNA was purified from buffy coat samples using the Qia-
gen QIAamp Blood Midi kit (Qiagen, CA, USA). ABCA1
gene promoter DNA methylation levels were measured
using pyrosequencing of sodium bisulfite-treated DNA, as
previously described [7]. Briefly, this gold standard tech-
nology for DNA methylation analysis is a simple, accurate
quantitative sequencing assay that combines sodium bisul-
fite DNA conversion, PCR amplification and sequencing
by synthesis (PyroMark Q24, Qiagen). PCR and se-
quencing primers were selected using the PyroMark Assay
Design v2.0.1.15 (Qiagen), as previously described [7]
(Additional file 1: Figure S1). DNA methylation levels
were measured at eight CpG dinucleotides upstream
from the first exon of the ABCA1 gene (ABCA1-CpG1
to -CpG8; Additional file 1: Figure S1). Considering that
DNA methylation levels were found to be well correlated
among these eight CpGs (r > 0.70; P < 0.001), a mean of
ABCA1 DNA methylation levels of these eight CpG dinu-
cleotides was thus computed for each subject and subse-
quently used in the statistical analyses.
Statistical analyses
The normal distribution of all variables was assessed using
the Kolmogorov-Smirnov test. Only fasting triglyceride
levels were not normally distributed and therefore log-10
transformed. Men were stratified into two groups accor-
ding to the median age: younger men (age <61 years old)
and older men (age ≥61 years old). Categorical variables
were compared using a Pearson χ2-statistic, whereas mean
differences between groups for continuous variables were
compared with an analysis of covariance including the fol-
lowing potential confounding factors: age, medication and
CAD status, and followed by Bonferroni’s post-hoc com-
parison test. Partial Pearson’s correlation was used to
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levels and plasma lipid concentrations after consideration
of the same confounding factors. Results were considered
statistically significant when P-values were <0.05 (two
sided). All statistical analyses were performed with the
IBM SPSS Statistic 20 software (release 20.0.0, SPSS, Inter-
national Business Machines (IBM) Corp., NY, USA).
Additional file
Additional file 1: Figure S1. ABCA1 gene promoter locus. The primary
DNA sequence was numbered relative to the first ABCA1 codon in exon 2
(Ensembl release 61 [February 2011]). The first exon of ABCA1 is in red
and bold type. The epigenotyped region is shown in green. Arrows
indicate both PCR primer sequences. The analysed CpG dinucleotides
have been numbered relative to the 5’ of the amplicon.
Abbreviations
ABCA1: ATP-binding cassette transporter A1; ASA: acetylsalicylic acid;
CAD: coronary artery disease; CRIUCPQ: Centre de Recherche de l’IUCPQ;
CVD: cardiovascular disease; FH: familial hypercholesterolemia; HDL-C: high-density
lipoprotein cholesterol; IUCPQ: Institut universitaire de cardiologie et de
pneumologie de Québec; LDL-C: low-density lipoprotein cholesterol;
NSAID: non-steroidal anti-inflammatory drug; PCR: polymerase chain reaction.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
S-PG conceived the study design, participated in the data collection, performed
the data analysis/interpretation and wrote the manuscript. CL performed data
collection and revised the manuscript. A-AH contributed to data analysis/
interpretation and revised the manuscript. YB and PM participated in the data
collection, analysis and interpretation and revised the manuscript. LB conceived
the study design, participated in the data analysis/interpretation process and
revised the manuscript. All authors read and approved the final manuscript.
Acknowledgments
The authors are thankful to all participants and the staff of the ECOGENE-21
Laboratory and Clinical Research Center and CRIUCPQ. We particularly
acknowledge the contribution of Céline Bélanger, Christine Racine and Nathalie
Gaudreault for their dedicated work. S-PG was recipient of a doctoral research
award from the Canadian Institutes for Health and Research (CIHR). CL was
recipient of a financial support from the Faculté de médecine et des sciences
de la santé (FMSS) de l’Université de Sherbrooke. A-AH was recipient of a Fonds
de recherche du Québec - Santé (FRQS) doctoral training award and was
supported by Diabète Québec. YB is the recipient of a Junior 2 Research Scholar
award from the FRQS. PM is a senior research scholar from the FRQS. LB is a
junior research scholar from the FRQS and a member of the FRQS-funded
Centre de recherche clinique du CHUS.
Author details
1Department of Biochemistry, Faculté de médecine et des sciences de la
santé, de l’Université de Sherbrooke, 3001 12e Avenue Nord, Sherbrooke,
Québec J1H 5 N4, Canada. 2ECOGENE-21 and Lipid Clinic, Chicoutimi Hospital,
305 rue St-Vallier, Saguenay, Québec G7H5H6, Canada. 3Centre de Recherche
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université
Laval, 2725 chemin Ste-Foy, Québec, Québec G1V 4G5, Canada. 4Department of
Molecular Medicine, Université Laval, 2325 rue de l’Université, Québec, Québec
G1V 0A6, Canada.
Received: 22 April 2014 Accepted: 17 July 2014
Published: 29 July 2014
References
1. Joyce C, Freeman L, Brewer HB Jr, Santamarina-Fojo S: Study of ABCA1
function in transgenic mice. Arterioscler Thromb Vasc Biol 2003, 23:965–971.2. Serfaty-Lacrosniere C, Civeira F, Lanzberg A, Isaia P, Berg J, Janus ED, Smith
MP Jr, Pritchard PH, Frohlich J, Lees RS, Barnard GF, Ordovas JM, Schaefer EJ:
Homozygous Tangier disease and cardiovascular disease. Atherosclerosis
1994, 107:85–98.
3. Wang J, Burnett JR, Near S, Young K, Zinman B, Hanley AJ, Connelly PW,
Harris SB, Hegele RA: Common and rare ABCA1 variants affecting
plasma HDL cholesterol. Arterioscler Thromb Vasc Biol 2000,
20:1983–1989.
4. Clee SM, Kastelein JJ, van Dam M, Marcil M, Roomp K, Zwarts KY, Collins JA,
Roelants R, Tamasawa N, Stulc T, Suda T, Ceska R, Boucher B, Rondeau C,
DeSouich C, Brooks-Wilson A, Molhuizen HO, Frohlich J, Genest J Jr, Hayden
MR: Age and residual cholesterol efflux affect HDL cholesterol levels and
coronary artery disease in ABCA1 heterozygotes. J Clin Invest 2000,
106:1263–1270.
5. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Steffensen R, Tybjaerg-Hansen A:
Genetic variation in ABCA1 predicts ischemic heart disease in the general
population. Arterioscler Thromb Vasc Biol 2008, 28:180–186.
6. Francis GA, Knopp RH, Oram JF: Defective removal of cellular cholesterol
and phospholipids by apolipoprotein A-I in Tangier disease. J Clin Invest
1995, 96:78–87.
7. Guay SP, Brisson D, Munger J, Lamarche B, Gaudet D, Bouchard L: ABCA1
gene promoter DNA methylation is associated with HDL particle profile
and coronary artery disease in familial hypercholesterolemia. Epigenetics
2012, 7:464–472.
8. Guay SP, Brisson D, Lamarche B, Gaudet D, Bouchard L: Epipolymorphisms
within lipoprotein genes contribute independently to plasma lipid levels
in familial hypercholesterolemia. Epigenetics 2014, 9:718–729.
9. Breton CV, Park C, Siegmund K, Gauderman WJ, Whitfield-Maxwell L, Hodis HN,
Avol E, Gilliland FD: NOS1 methylation and carotid artery intima-media
thickness in children. Circ Cardiovasc Genet 2014, 7:116–122.
10. Sharma P, Garg G, Kumar A, Mohammad F, Kumar SR, Tanwar VS, Sati S,
Sharma A, Karthikeyan G, Brahmachari V, Sengupta S: Genome wide DNA
methylation profiling for epigenetic alteration in coronary artery disease
patients. Gene 2014, 541:31–40.
11. Zhuang J, Peng W, Li H, Wang W, Wei Y, Li W, Xu Y: Methylation of
p15INK4b and expression of ANRIL on chromosome 9p21 are associated
with coronary artery disease. PLoS One 2012, 7:e47193.
12. Jiang D, Zheng D, Wang L, Huang Y, Liu H, Xu L, Liao Q, Liu P, Shi X, Wang Z,
Sun L, Zhou Q, Li N, Le Y, Ye M, Shao G, Duan S: Elevated PLA2G7 gene
promoter methylation as a gender-specific marker of aging increases the
risk of coronary heart disease in females. PLoS One 2013, 8:e59752.
13. Xu L, Zheng D, Wang L, Jiang D, Liu H, Liao Q, Zhang L, Liu P, Shi X,
Wang Z, Sun L, Zhou Q, Li N, Huang Y, Le Y, Ye M, Shao G, Duan S: GCK
gene-body hypomethylation is associated with the risk of coronary heart
disease. Biomed Res Int 2014, 2014:151723.
14. Houde AA, Guay SP, Desgagne V, Hivert MF, Baillargeon JP, St-Pierre J, Perron
P, Gaudet D, Brisson D, Bouchard L: Adaptations of placental and cord blood
ABCA1 DNA methylation profile to maternal metabolic status. Epigenetics
2013, 8:1289–1302.
15. Liang Y, Yang X, Ma L, Cai X, Wang L, Yang C, Li G, Zhang M, Sun W, Jiang
Y: Homocysteine-mediated cholesterol efflux via ABCA1 and ACAT1 DNA
methylation in THP-1 monocyte-derived foam cells. Acta Biochim Biophys
Sin (Shanghai) 2013, 45:220–228.
16. Bird A: DNA methylation patterns and epigenetic memory. Genes Dev
2002, 16:6–21.
17. Tobi EW, Lumey LH, Talens RP, Kremer D, Putter H, Stein AD, Slagboom PE,
Heijmans BT: DNA methylation differences after exposure to prenatal
famine are common and timing- and sex-specific. Hum Mol Genet 2009,
18:4046–4053.
18. Talens RP, Christensen K, Putter H, Willemsen G, Christiansen L, Kremer D,
Suchiman HE, Slagboom PE, Boomsma DI, Heijmans BT: Epigenetic
variation during the adult lifespan: cross-sectional and longitudinal data
on monozygotic twin pairs. Aging Cell 2012, 11:694–703.
19. Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H: Tobacco-smoking-related
differential DNA methylation: 27 K discovery and replication. Am J Hum
Genet 2011, 88:450–457.
20. Barres R, Yan J, Egan B, Treebak JT, Rasmussen M, Fritz T, Caidahl K, Krook A,
O'Gorman DJ, Zierath JR: Acute exercise remodels promoter methylation
in human skeletal muscle. Cell Metab 2012, 15:405–411.
21. Ronn T, Volkov P, Davegardh C, Dayeh T, Hall E, Olsson AH, Nilsson E,
Tornberg A, Dekker Nitert M, Eriksson KF, Jones HA, Groop L, Ling C: A six
Guay et al. Clinical Epigenetics 2014, 6:14 Page 7 of 7
http://www.clinicalepigeneticsjournal.com/content/6/1/14months exercise intervention influences the genome-wide DNA methylation
pattern in human adipose tissue. PLoS Genet 2013, 9:e1003572.
22. Jacobsen SC, Gillberg L, Bork-Jensen J, Ribel-Madsen R, Lara E, Calvanese V,
Ling C, Fernandez AF, Fraga MF, Poulsen P, Brons C, Vaag A: Young men
with low birthweight exhibit decreased plasticity of genome-wide
muscle DNA methylation by high-fat overfeeding. Diabetologia 2014,
57:1154–1158.
23. Chang PY, Chen YJ, Chang FH, Lu J, Huang WH, Yang TC, Lee YT, Chang SF,
Lu SC, Chen CH: Aspirin protects human coronary artery endothelial cells
against atherogenic electronegative LDL via an epigenetic mechanism:
a novel cytoprotective role of aspirin in acute myocardial infarction.
Cardiovasc Res 2013, 99:137–145.
24. Kodach LL, Jacobs RJ, Voorneveld PW, Wildenberg ME, Verspaget HW, van
Wezel T, Morreau H, Hommes DW, Peppelenbosch MP, van den Brink GR,
Hardwick JC: Statins augment the chemosensitivity of colorectal cancer
cells inducing epigenetic reprogramming and reducing colorectal cancer
cell ‘stemness’ via the bone morphogenetic protein pathway. Gut 2011,
60:1544–1553.
25. Vinals M, Bermudez I, Llaverias G, Alegret M, Sanchez RM, Vazquez-Carrera M,
Laguna JC: Aspirin increases CD36, SR-BI, and ABCA1 expression in human
THP-1 macrophages. Cardiovasc Res 2005, 66:141–149.
26. Ranga GS, Kalra OP, Tandon H, Gambhir JK, Mehrotra G: Effect of aspirin on
lipoprotein (a) in patients with ischemic stroke. J Stroke Cerebrovasc Dis
2007, 16:220–224.
27. Sethi A, Parmar HS, Kumar A: The effect of aspirin on atherogenic
diet-induced diabetes mellitus. Basic Clin Pharmacol Toxicol 2011,
108:371–377.
28. Charan J, Goyal JP, Saxena D: Effect of Pollypill on cardiovascular
parameters: systematic review and meta-analysis. J Cardiovasc Dis Res
2013, 4:92–97.
29. Pereira MA, Tao L, Wang W, Li Y, Umar A, Steele VE, Lubet RA: Modulation
by celecoxib and difluoromethylornithine of the methylation of DNA
and the estrogen receptor-alpha gene in rat colon tumors. Carcinogenesis
2004, 25:1917–1923.
30. Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Okubo M,
Maruyama N, Kamano T, Kamiya Y, Fujita H, Nagasaka M, Iwata M, Takahama
K, Watanabe M, Hirata I, Arisawa T: Chronic aspirin use suppresses CDH1
methylation in human gastric mucosa. Dig Dis Sci 2010, 55:54–59.
31. Cheong HS, Park SM, Kim MO, Park JS, Lee JY, Byun JY, Park BL, Shin HD,
Park CS: Genome-wide methylation profile of nasal polyps: relation to
aspirin hypersensitivity in asthmatics. Allergy 2011, 66:637–644.
32. Noreen F, Röösli M, Gai P, Pietrzak J, Weis S, Urfer P, Regula J, Schär P,
Truninger K: Modulation of age- and cancer-associated DNA methylation
change in the healthy colon by aspirin and lifestyle. J Natl Cancer Inst
2014, 106.
33. Guay SP, Voisin G, Brisson D, Munger J, Lamarche B, Gaudet D, Bouchard L:
Epigenome-wide analysis in familial hypercholesterolemia identified new
loci associated with high-density lipoprotein cholesterol concentration.
Epigenomics 2012, 4:623–639.
34. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L,
Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A,
Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C,
Averna M, Boren J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P,
Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjaerg-Hansen A, European
Atherosclerosis Society Consensus Panel: Familial hypercholesterolaemia is
underdiagnosed and undertreated in the general population: guidance
for clinicians to prevent coronary heart disease: consensus statement of
the European Atherosclerosis Society. Eur Heart J 2013, 34:3478–3490.
doi:10.1186/1868-7083-6-14
Cite this article as: Guay et al.: Acetylsalicylic acid, aging and coronary
artery disease are associated with ABCA1 DNA methylation in men.
Clinical Epigenetics 2014 6:14.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
